During our research, we were able to identify close to 80 bioprinters and smart biomaterials that are in different stages of development for the treatment of various diseases.

With an aim to counter the increasing number of cancer cases, researchers across the globe have developed AI-based solutions for the early diagnosis of a wide range of cancer indications.

Genotoxicity refers to the property of physical, chemical, and biological agents to cause damage to genetic information present within a cell. It is worth mentioning that this damage can lead to formation of mutations, activation of mistimed event and direct DNA damage.

Roots Analysis have analyzed patents based on various relevant parameters, such as type of patent, patent publication year, annual number of patent applications, type of applicant, emerging focus areas, and geographical location.

Over the past 50 years, the medical device industry has seen several notable developments. In fact, the use of biomedical devices, such as medical implants, surgical instruments, and prostheses has increased substantially over the time.

Long-acting drug delivery has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level.

Modified tumor-infiltrating lymphocytes (TIL)-based interventions have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects.

Driven by the growing demand for digital and remote health solutions, the digital therapeutics market is likely to witness 20% annual growth in the short to mid term

In recent years, advancements in technology and emphasis on precision medicine have recently paved the path for the development of artificial intelligence (AI) based digital pathology techniques for quantitative and qualitative assessment of samples.

Dental 3D printing market, driven by over 230 dental 3D printers being development or available in the market, is expected grow at over 14% CAGR

A number of biopharmaceutical companies are outsourcing their biologics fill / finish operations, thereby, prompting stakeholders engaged in this domain to undertake several expansion initiatives, to cater to the needs of clients around the globe.

SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share

Given the recent approval of a TCR-based therapy, industry stakeholders have initiated several R&D efforts focused on evaluating the potential of such therapy candidates against various disease indications

Owing to organ scarcity and lesser number of donors, the demand for tissue engineering and organ reconstruction has increased notably; as a result, the adoption of advanced 4D bioprinting technology is anticipated to increase over the coming years

Given the potential of digital twins to replicate the physical world in a digital layout, as well as their ability to provide real-time outputs, while gathering constant inputs from the real-world, such products have generated significant interest within the healthcare domain

Over the years, several advanced and innovative automation tools and technologies have been developed; these have been demonstrated to hold the potential for significant reduction in the cost associated with the manufacturing of advanced therapy medicinal products, thereby, making such products more affordable.

Driven by the development of advanced methods for preparation and characterization of liposomes, and the application of these molecules in therapeutics and diagnostics, the demand for liposomes is expected to rise in the coming years.

SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share

In order to overcome the limitations and challenges related to animal testing, researchers and industry stakeholders are gradually adopting organ-on-chip products and technologies, which offer multiple benefits over conventional systems.